Displaying 1 - 20 of 38

WCC reflects on women’s transformative leadership at international conference on innovation in Africa

Prof. Ezra Chitando, World Council of Churches (WCC) Ecumenical HIV and AIDS Initiatives and Advocacy regional coordinator for Southern Africa, presented on behalf of WCC deputy general secretary Prof. Dr Isabel Apawo Phiri, a paper on Womens Transformative Leadership and Africas Holistic Development: The Role of the Churches” during an international conference on leadership transformation and innovation in Africa.

New and old epidemics in focus at WCC gathering in Nairobi

Two World Council of Churches (WCC) HIV initiatives met to review and celebrate the critical and life-changing work of the initiatives and to continue planning for a strengthened WCC HIV response in the new WCC Commission of the Churches on Health and Healing.

Prof. Mary-Anne Plaatjies-Van Huffel: „Wir gestalten Theologie neu“

Prof. Mary-Anne Plaatjies-Van Huffel ist Präsidentin des Ökumenischen Rates der Kirchen (ÖRK) für Afrika. Sie ist eine südafrikanische Pastorin und Akademikerin und die erste Frau, die von einer Holländischen Reformierten Kirche im südlichen Afrika in einem geistlichen Amt ordiniert wurde. Vor Kurzem wurde sie an der Universität Stellenbosch zur ordentlichen Professorin für Kirchengeschichte und Kirchenrecht ernannt.

Prof. Mary-Anne Plaatjies-Van Huffel: “we are redesigning theology”

Prof. Mary-Anne Plaatjies-Van Huffel is the World Council of Churches (WCC) president for Africa. A South African pastor and academic, she was the first female minister to be ordained by a Dutch Reformed Church in Southern Africa. She has recently been promoted to full professor of church history and church law, at the University Stellenbosch.

Mission and people with disabilities

How much is the mission of the church related to people with disabilities? These days we talk a lot about inclusive societies and churches. But, have we arrived there? Are our societies and churches taking seriously the problems and challenges that people with disabilities face on a daily basis? People with disabilities find themselves quite often at the margins of the societies and even of the churches.

New issue: International Review of Mission

The latest issue of the International Review of Mission, the biannual journal of the WCC contains a selection of articles which were on the one hand given as key lectures at the Conference on World Mission and Evangelism in Arusha from 8-13 March 2018 and on the other hand articles from Missiologists from all over the world, including Catholic, Pentecostal, Protestant and Orthodox voices, asking about “Mission quo vadis after Arusha?”.

Konrad Raiser spricht über den ökumenischen Weg der Verwandlung

Während fast seines gesamten Erwachsenenlebens war Konrad Raiser auf einem ökumenischen Weg unterwegs. Der ehemalige ÖRK-Generalsekretär spricht in seiner neusten Veröffentlichung „The Challenge of Transformation: An Ecumenical Journey“ über diesen Pilgerweg. Am 5. Februar, kurz nach Raisers 80. Geburtstag, trafen sich in Genf verschiedene Generationen, Konfessionen und Nationalitäten zur Diskussion über das eben erschienene Buch.

Konrad Raiser shares ecumenical journey of transformation

Rev. Dr Konrad Raiser has been on an ecumenical journey for most of his adult life, which spans 80 years. The former WCC general secretary relates some of this pilgrimage in his newest publication, “The Challenge of Transformation: An Ecumenical Journey.” On 5 February, shortly after Raiser’s birthday, ecumenical experts from different generations, confessions and continents met in Geneva to discuss the newest publication by the man who led the WCC from 1993 to 2003.

“Good healthcare a right, not a privilege,” says WCC-EAA

The World Council of Churches - Ecumenical Advocacy Alliance endorses a newly expanded collaboration on HIV between the Medicine Patent Pool and Gilead. On 4 October, the MPP announced a licence with Gilead Sciences for bictegravir, a new integrase inhibitor part of a once-daily, single-tablet HIV regimen currently filed for regulatory approval at the United States Food and Drug Administration and the European Union.